Re-Purposing Evodiamine as an Anti-Cancer Drug: Effects on Migration and Apoptosis

Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 3

Abstract

Introduction: Evodiamine is a quinolone alkaloid compound obtained from a fruit described in traditional Chinese medicine. It has been in use for many centuries for the treatment of headaches, menstrual problems, abdominal pain and other ailments. In the western world, it is known as a controversial weight loss product and is sold over the counter as a nutritional supplement. Many freely sold weight loss products contain evodiamine associated with other supposed weight control chemicals. Even though there are no reliable statistics, we may presume that thousands of persons have been using it without serious side effects being reported. Background: At the beginning of this century researchers found that this compound had anti-cancer effects: cytotoxicity and decreased invasion and migration in vitro in malignant cells while showing minimal damage to normal cells. Little has been investigated about in vivo effects on cancer. There is a lack of information regarding the possibility of achieving the clinical concentrations needed for tumour cytotoxicity and for inhibiting migration. Objectives: The goal of this study was to determine the feasibility of re-purposing evodiamine as an anti-cancer drug. For this, we investigated: a. the possibility of achieving the cytotoxic concentrations of the drug required at tumor level in the clinical setting; b. the molecular mechanisms responsible for the anti-cancer effects; c. which types of tumours can be treated; d. its interrelation with other chemotherapeutics; e. Interrelation of evodiamine with berberine in anti-cancer effects. Material and Methods: Due to the abundance of published research on evodiamine, many ofthe objectives could be accomplished by reviewing the literature, introducing a systematic search, and organizing the findings. Results: The necessary concentrations to achieve possible clinical results may be reached through oral administration. This concept applies mainly to inhibition of migration, that requires a low concentration. The cytotoxic effects need higher concentrations that are not easily attainable with standard preparations. An association with berberine, a non-toxic compound, increases evodiamine's cytotoxicity. Almost all malignancies, whether solid or hematologic, are affected by evodiamine in a dose dependent manner. Evodiamine may also complement the activity of other chemotherapeutics like campthotecin, taxanes, doxoubicin and probably radiotherapy as well. Conclusion: Evodiamine should be tested in humans to establish the achievable plasma concentrations, because all the published pharmacodynamic reports were based on tests on rodents. Whether alone or associated with berberine, evodiamine,deserves to be tested in well designed clinical trials for the treatment of cancer and prevention of metastasis.

Authors and Affiliations

Tomas Koltai

Keywords

Related Articles

A Note on Mushroom Immunomodulation and its Potential on Prevention of Cancer

Patterns of diseases and resulting well-being, morbidity and mortality have changed considerably in the last decades namely in developed countries. Infection-contagious diseases are no longer a major threat and other chr...

Main Components of Liquid Biopsy are Greater than it Seems?

Long time ago it was wrongly thought that tumor genes and cells are only existence in the exact tumor site. In spite of the fact of the hypothesis that circulating tumor cells (CTCs) are a fundamental prerequisite to met...

Targeting the Immune Checkpoint in Cancer: Is This a Viable Treatment Option for AML?

The immune suppressive mechanisms displayed by malignant cells are considered a central process in the pathogenesis of cancer. Research in this area has gained significant momentu mover the past 20 years, with several im...

Spinal Meningioma: Pathophysiology, Diagnosis and Management

Tumors have several types that can build up in or near the spine. There are many types of spinal tumors. They can appoint the spinal cord, nerve roots or the vertebrae (bones of the spine) and pelvis. Spinal tumors have...

Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment

In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphat...

Download PDF file
  • EP ID EP583065
  • DOI 10.32474/OAJOM.2018.01.000111
  • Views 91
  • Downloads 0

How To Cite

Tomas Koltai (2018). Re-Purposing Evodiamine as an Anti-Cancer Drug: Effects on Migration and Apoptosis. Open Access Journal of Oncology and Medicine, 1(3), 37-51. https://europub.co.uk/articles/-A-583065